Key result
Statins may benefit primary CVD prevention in older adults without life-limiting comorbidities.
Why the study?
The role of statins for primary CVD prevention in older adults remains unclear, largely due to systematic exclusion of these individuals from trials, leading to conflicting practice recommendations in adults aged 75 and older.
Does statin therapy prevent cardiovascular disease in older adults without established cardiovascular disease?
Does statin therapy prevent cardiovascular disease in older adults without established cardiovascular disease?
This review highlights the potential benefit of statins for primary CVD prevention in healthy older adults and emphasizes the need for individualized, shared decision-making.
Supports statin consideration in healthy older adults; leaves open need for dedicated RCTs to resolve guideline conflicts.
INTRODUCTION: Cardiovascular disease (CVD) is associated with significant morbidity, functional decline, and mortality in older adults. The role of statins for primary CVD prevention in older adults remains unclear, largely due to systematic exclusion of these individuals in trials that inform current practice guidelines, leading to conflicting national and international practice recommendations for statin use for primary prevention of CVD in adults aged 75 and older. AREAS COVERED: In this narrative review, we performed a literature review utilizing PubMed, and ultimately focus on seven major national and international guidelines of lipid lowering therapy. Through the lens of two clinical cases, we review physiologic changes in lipid metabolism with aging, discuss the relationship between cholesterol and cardiovascular events in older adults, examine the national and international guidelines and the available evidence informing these guidelines for statin use in primary prevention of CVD in older adults. Finally we review practical clinical considerations for drug monitoring and deprescribing in this population. EXPERT OPINION: Guidelines for the use of statins for primary CVD prevention in older adults is conflicting. Collectively, evidence to date suggests statin therapy may be beneficial for primary CVD prevention in older adults free of life-limiting comorbidities. Randomized controlled trials are currently underway to address current evidence gaps.
No takes yet. Share an insight, caveat, or question.
Stone et al. (2024) conducted a review in Cardiovascular disease (primary prevention). Statin therapy vs. No statin therapy or placebo was evaluated. Statin therapy may be beneficial for primary cardiovascular disease prevention in older adults free of life-limiting comorbidities, despite conflicting guidelines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: